title: [Vasculogenic mimicry and mosaic vessels and targeted therapy in renal cell carcinoma].
abstract: Renal cell carcinoma is one of the most common malignant tumors of urinary system. The annual incidence rate is approximately 17.9/100 000 populations, and there is a continually rising trend in number of new diagnosis. Metastatic and high-risk renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy and/or radiotherapy. Although cytokine-based therapies (interferon and interleukin-2) have been widely used, their effectiveness remained unsatisfactory due to their low response rates and short survival. Drugs targeting anti-angiogenesis pathways have shown benefits in relapse-free survival. In this review, we introduce the recent advances in the treatment of renal cancer, especially the application of vasculogenic mimicry and mosaic vessels. Although targeted therapies with anti-angiogenic properties have proposed new treatment criteria for advanced renal cell carcinoma, new drugs or new combinations are needed to improve the clinical efficacy and minimize adverse effects.
authors: Department of Urology, PUMC Hospital, CAMS and PUMC, Beijing, China.
authors: Jian-hua
authors: JH
authors: Deng
authors: Han-zhong
authors: HZ
authors: Li
mesh_terms: D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000628:therapy*